JCI Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop

Taiwanese team develops new treatment for triple-negative breast cancer - Focus Taiwan

Taipei, July 3 (CNA) A Taiwanese medical team has developed a new treatment for triple-negative breast cancer (TNBC) that tackles treatment-resistance, announced National Health Research Institutes (NHRI) President Sytwu Huey-kang (司徒惠康) on Thursday.

JCI Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop

Triple-negative breast cancer (TNBC) represents the most malignant subtype of breast cancer. The clinical application of PARP inhibitors (PARPi) is limited by the low frequency of BRCA1/2 mutations in TNBC. Here, we identified that MTAP deletion sensitized genotoxic agents in our clinical cohort of metastatic TNBC. Further study demonstrated that MTAP deficiency or inhibition rendered TNBC susceptibility to chemotherapeutic agents, particularly …